Chia Kow to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Chia Kow has written about Randomized Controlled Trials as Topic.
Connection Strength
0.527
-
Pitfalls in Reporting Sample Size Calculation Across Randomized Controlled Trials Involving Ivermectin for the treatment of COVID-19. Am J Ther. 2021 08 06; 28(5):e616-e619.
Score: 0.233
-
Renin-angiotensin system inhibitor use and the risk of mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials. Hypertens Res. 2021 08; 44(8):1042-1045.
Score: 0.057
-
The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis. Pharmacol Rep. 2021 Oct; 73(5):1473-1479.
Score: 0.057
-
The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2021 Aug; 77(8):1089-1094.
Score: 0.056
-
Effect of remdesivir on mortality in patients with COVID-19: A meta-analysis of randomized control trials. J Med Virol. 2021 04; 93(4):1860-1861.
Score: 0.055
-
Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials? Int J Infect Dis. 2020 Dec; 101:107-120.
Score: 0.055
-
The use of remdesivir for the management of patients with moderate-to-severe COVID-19: a systematic review. Expert Rev Anti Infect Ther. 2022 02; 20(2):211-229.
Score: 0.015